

# Sustainability Accounting Standards Board (SASB) index 2024

The Novartis SASB index aligns with the Biotechnology & Pharmaceuticals Sustainability Accounting Standard (industry standard | version 2023-12). Data and information referenced are sourced from the Novartis 2024 annual reporting suite (Novartis in Society Integrated Report and Annual Report/Form 20-F), our corporate website, Novartis public policies and positions, and public databases or selected materials from third parties where applicable.

SASB indicator		Reference	SASB indicator		Reference
<b>Safety of Clinical Trial Participants</b>			<b>Counterfeit Drugs</b>		
HC-BP-210a.1	Discussion, by region, of management process for ensuring quality and patient safety during clinical trials	<a href="#">p. 38-39 Novartis Commitment to Patients and Caregivers Human Rights Commitment Statement Ethics in Clinical Trials</a>	HC-BP-260a.1	Description of methods and technologies used to maintain traceability of products throughout the supply chain and prevent counterfeiting	<a href="#">p. 39 Novartis Position on Falsified Medical Products</a>
HC-BP-210a.2	Number of inspections related to clinical trial management and pharmacovigilance that resulted in: (1) entity voluntary remediation or (2) regulatory or administrative actions taken against the entity	<a href="#">p. 39 ESG Index: Quality</a>	HC-BP-260a.2	Discussion of process for alerting customers and business partners to potential or known risks associated with counterfeit products	<a href="#">p. 39</a>
HC-BP-210a.3	Total amount of monetary losses as a result of legal proceedings associated with clinical trials in developing countries	All significant legal proceedings are disclosed within the Annual Report and accounts ( <a href="#">Annual Report</a> ).	HC-BP-260a.3	Number of actions that led to raids, seizure, arrests, or filing of criminal charges related to counterfeit products	<a href="#">p. 39</a>
<b>Access to Medicines</b>			<b>Ethical Marketing</b>		
HC-BP-240a.1	Description of actions and initiatives to promote access to health care products for priority diseases and in priority countries as defined by the Access to Medicine Index	<a href="#">p. 40-41 Access to Medicines Index</a>	HC-BP-270a.1	Total amount of monetary losses as a result of legal proceedings associated with false marketing claims	<a href="#">Annual Report</a>
HC-BP-240a.2	List of products on the WHO List of Prequalified Medicinal Products as part of its Prequalification of Medicines Programme (PQP)	Novartis has malaria products on the WHO List of Prequalified Medicinal Products.	HC-BP-270a.2	Description of code of ethics governing promotion of off-label use of products	<a href="#">p. 42 Code of Ethics Doing Business Ethically policy</a>
<b>Affordability &amp; Pricing</b>			<b>Employee Recruitment, Development &amp; Retention</b>		
HC-BP-240b.2	Percentage change in: (1) weighted average list price and (2) weighted average net price across product portfolio compared to previous reporting period	not reported	HC-BP-330a.1	Discussion of talent recruitment and retention efforts for scientists and research and development personnel	<a href="#">p. 34 Careers Research &amp; Development US Biomedical Research Internship Programs</a>
HC-BP-240b.3	Percentage change in: (1) list price and (2) net price of product with largest increase compared to previous reporting period	not reported	HC-BP-330a.2	(1) Voluntary and (2) involuntary turnover rate for: (a) executives/senior managers, (b) midlevel managers, (c) professionals, and (d) all others	<a href="#">p. 60</a>
<b>Drug Safety</b>			<b>Supply Chain Management</b>		
HC-BP-250a.1	Products listed in any public medical product safety or adverse event alert database	<a href="#">Available via FDA Adverse Event Reporting website</a>	HC-BP-430a.1	Percentage of (1) entity's facilities and (2) Tier I suppliers' facilities participating in the Rx-360 International Pharmaceutical Supply Chain Consortium audit program or equivalent third-party audit programs for integrity of supply chain and ingredients	<a href="#">p. 46 Novartis Quality Management System (QMS) External Partner Risk Management (EPRM)</a>
HC-BP-250a.2	Number of fatalities associated with products	<a href="#">Available via FDA Adverse Event Reporting website</a>	<b>Business Ethics</b>		
HC-BP-250a.3	(1) Number of recalls issued, (2) total units recalled	<a href="#">p. 39</a>	HC-BP-510a.1	Total amount of monetary losses as a result of legal proceedings associated with corruption and bribery	<a href="#">Annual Report</a>
HC-BP-250a.4	Total amount of product accepted for takeback, reuse, or disposal	<a href="#">p. 39</a>	HC-BP-510a.2	Description of code of ethics governing interactions with health care professionals	<a href="#">p. 42 Code of Ethics Doing Business Ethically policy</a>
HC-BP-250a.5	Number of enforcement actions taken in response to violations of Good Manufacturing Practices (GMP) or equivalent standards, by type	<a href="#">ESG Index: Quality</a>	<b>Activity Metrics</b>		
			HC-BP-000.A	Number of patients treated	<a href="#">p. 40</a>
			HC-BP-000.B	Number of drugs (1) in portfolio and (2) in research and development (Phases 1-3)	(1) <a href="#">Novartis products</a> (2) <a href="#">p. 22-23</a>